Next Generation Drug Conjugates Market Size was valued at USD 2.61 Bn in 2023 and is predicted to reach USD 7.94 Bn by 2031 at a 15.1% CAGR during the forecast period for 2024-2031.
The next-generation drug conjugates (NGDCs) market represents a paradigm shift in cancer therapy, leveraging the synergistic potential of targeted drug delivery and enhanced therapeutic efficacy. NGDCs are a class of bioconjugates that combine cytotoxic payloads with specific targeting moieties, allowing for precise delivery to cancer cells while minimizing off-target effects. This innovative approach has garnered attention in the healthcare industry due to its potential to overcome the limitations of traditional chemotherapy and improve patient outcomes.
The COVID-19 pandemic significantly impacted the Next Generation Drug Conjugates (NGDC) market. While demand for innovative therapies rose, disruptions in supply chains, clinical trials, and healthcare access led to delays in development and commercialization. Additionally, shifting healthcare priorities and economic uncertainties affected investment patterns. However, the pandemic also accelerated digital adoption, facilitating remote work and telemedicine, which could streamline R&D processes. As the healthcare sector adapts to post-pandemic realities, the NGDC market may see renewed growth opportunities driven by advancements in technology, increasing focus on personalized medicine, and the need for more effective treatments against evolving diseases.
Competitive Landscape
Some of the Major Key Players in the Next Generation Drug Conjugates Market are
- Advanced Accelerator Applications
- Alnylam Pharmaceuticals
- Arrowhead Pharmaceuticals
- Dicerna Pharmaceuticals
- Geron Corporation
- Ionis Pharmaceuticals
- Dyne Therapeutics, Inc.
- Ambrx Biopharma, Inc. (Johnson & Johnson Services, Inc.)
- Vincerx Pharma
- Tubulis Technologies
- Nurix Therapeutics, Inc.
- Other Prominent Players
Market Segmentation:
The next generation drug conjugates (NGDC) market can be segmented into type, targeting ligand, payload, therapy, route of administration, and indications. By Type, the market is segmented into peptide receptor radionuclide therapy (peptide radionuclide conjugate), ligand-mediated RNAi conjugate, ligand conjugated antisense medicine, and peptide drug conjugate. The market is segmented by targeting ligands into amino sugar, lipid, peptide, small molecule, and virus-like particles. The market is divided by a peptide, small molecule, oligonucleotide, and radionuclide by payload. By therapy, the market is segmented into monotherapy and combination therapy. Based on route of administration, the market is segmented into intravenous, subcutaneous, and others; by indications, the market is segmented into gastroenteropancreatic neuroendocrine tumors, prostate cancer, leptomeningeal carcinomatosis caused by breast cancer brain metastases, hereditary transthyretin amyloidosis, atherosclerotic cardiovascular diseases, severe hypertriglyceridemia, hereditary angioedema, acute hepatic porphyria, primary hyperoxaluria, heterozygous familial hypercholesterolemia, hemophilia, low-risk myelodysplastic syndrome, myelofibrosis, familial chylomicronemia syndrome, Alpha-1 antitrypsin deficiency liver disease.
Based on the Type, the Peptide Radionuclide Conjugate Segment Accounts for a Major Contributor in the Next Generation Drug Conjugates (NGDC) Market
Among the various types in the next generation drug conjugates (NGDC) market, the peptide radionuclide conjugate (PRC) segment is a prominent contributor. PRCs combine peptides with radioactive isotopes to create targeted therapies for cancer and other diseases. They work by delivering the radioactive material directly to cancer cells, minimizing damage to healthy tissues. This targeted approach enhances efficacy while reducing side effects compared to traditional chemotherapy. The PRC segment's innovation in precision medicine and its potential to revolutionize cancer treatment make it a major player in the NGDC market, attracting significant attention from researchers and investors alike.
The Amino Sugar Segment Dominate the Market
Based on targeting ligands, the amino sugar segment is experiencing rapid growth. Amino sugars, like glucosamine and galactosamine, serve as targeting ligands in drug conjugates. These ligands can specifically recognize and bind to certain receptors or proteins overexpressed on cancer cells, delivering the drug payload directly to the target site. This targeted delivery enhances the efficacy of the treatment while minimizing off-target effects. The increasing understanding of tumor biology and the development of novel targeting ligands contribute to the rapid growth of the Amino Sugar segment, making it a key area of focus in the drug conjugates market.
North America Region Hold a Significant Revenue Share
The North American next-generation drug conjugates market is predicted to have a significant market share in revenue. In the next-generation drug conjugates (ADCs) market, North America holds a prominent position, operated by factors such as research and development activities, robust healthcare infrastructure, and high prevalence of cancer. The region boasts key market players and favorable regulatory policies, fostering innovation and commercialization of ADC therapies. Additionally, increasing investments in oncology research and the growing adoption of novel treatment modalities further propel the growth of the next generation drug conjugates market in North America.
Recent Developments:
- In April 2023, Novartis entered into a licensing agreement with 3B Pharmaceuticals. 3B Pharmaceuticals is a German-based company involved in the growth of peptide receptor radionuclide therapy (PRRT) candidates targeting fibroblast activation protein (FAP) receptors.
- In March 2023, Japan-based PeptiDream signed strategic partnership with US-based RayzeBio to develop a peptide-radioisotope (RI) conjugate against Glypican-3 ("GPC3") expressed in liver cancers.
- In March 2023, The USFDA accepted Ionis Pharmaceutical's New Drug Application (NDA) for its investigational antisense medication Eplontersen, which is intended for patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). After Amvuttra (vutrisiran) from Alnylam, Eplontersen will be the second medication licensed for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Global Next Generation Drug Conjugates Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 2.61 Bn |
|
Revenue Forecast In 2031 |
USD 7.94 Bn |
|
Growth Rate CAGR |
CAGR of 15.1% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, By Targeting Ligand, By Payload, By Therapy, By Route of Administration, By Indications and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Advanced Accelerator Applications, Alnylam Pharmaceutical, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Geron Corporation, and Ionis Pharmaceuticals, Dyne Therapeutics, Inc., Ambrx Biopharma, Inc. (Johnson & Johnson Services, Inc.), Vincerx Pharma, Tubulis Technologies, Nurix Therapeutics, Inc., Other Prominent Players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
